Lenograstim
As of the edition of 20 October 2026, Lenograstim is a protein: marketed, first approved in 1991 (JP); acts on CSF3R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Protein
- Brand name
- Granocyte
- First approved
- 1 December 1991 (JP)
- Approvals on record
- 4 in 3 regions
- Holder of the most recent approval
- Roche; 3 holders in all
- Registered trials
- 16, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Skin and connective tissue; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Lenograstim.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CSF3R | Granulocyte colony-stimulating factor receptor | Q99062 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 0 |
| Phase 1 | 1 | 0 | 0 | 0 |
| Phase 2 | 3 | 2 | 0 | 0 |
| Phase 3 | 7 | 5 | 0 | 1 |
| Phase 4 | 3 | 2 | 1 | 0 |
| All trials | 16 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Roche | Originator | 1991 to now |